Compare BridgeBio Pharma Inc (BBIO) vs Vanguard Total International Bond Index Fund ETF (BNDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Vanguard Total International Bond Index Fund ETF — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.36B), while Vanguard Total International Bond Index Fund ETF trades at $47.93. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, Vanguard Total International Bond Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| BBIO | BNDX | |
|---|---|---|
Market Cap | $16.36B | — |
Sector | Health | — |
52-Week High | $90.17 | $49.91 |
52-Week Low | $47.29 | $47.57 |
Enterprise Value | $18.14B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Vanguard Total International Bond Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the Bloomberg Global Aggregate ex-USD Float Adjusted RIC Capped Index (USD Hedged). This index provides a broad-based measure of the global, investment-grade, fixed-rate debt markets. It is non-diversified.
Read more on BNDX →
